Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
MT PLEASANT, S.C., May 6, 2025, 10:12 GMT-04
Paradigm-Therapeutics
Read full article →